Research products
Tirzepatide
EUR 44.99
Product Overview
Research use only
Tirzepatide is a long-acting synthetic peptide agonist of both the GIP and GLP-1 receptors. It is an approved active substance marketed in the EU as Mounjaro for type 2 diabetes and weight-management-related indications, with regulatory information updated by EMA in August 2026.
Product information
Research areas include dual incretin receptor pharmacology, insulin secretion, glucose metabolism, appetite/energy-balance pathways and receptor signalling. Tirzepatide is a modified 39-amino-acid peptide with a fatty-diacid moiety that contributes to prolonged exposure. A bulk research vial is not equivalent to the authorized Mounjaro finished product.